Viatris (VTRS) has been receiving significant attention from law firms Faruqi & Faruqi, Rosen, Howard G. Smith, Bronstein, and Gewirtz & Grossman, with allegations against the company being investigated. This has caused its share price to plummet in 2025. Despite this, Viatris reported positive financial results for the 2nd, 3rd and 4th quarters of 2024 and also provided 2025 financial guidance. It has even maintained its dividend policy for 2025 and announced a quarterly dividend. Viatris has announced several significant milestones, such as new drug applications, FDA approval of treatments, and important divestitures. Moreover, the company has appointed Scott A. Smith as its new CEO effective April 1, 2023. The company also launched Breyna, the first FDA-approved generic version of Symbicort. Despite the volatility of Viatris's stock, currently at 3.27%, these positive events suggest potential future stability.
Viatris VTRS News Analytics from Mon, 27 Feb 2023 08:00:00 GMT to Sat, 15 Mar 2025 13:36:07 GMT -
Rating -4
- Innovation 0
- Information 2
- Rumor -5
